Oct 25,2022

How Dexcom uses wearables to deliver differentiated diabetes management

Dexcom is one of the leaders in the diabetes technology space with its continuous glucose monitoring (CGM) technology. The company’s current-generation Dexcom G6 CGM remains one of the biggest players in the CGM space. Meanwhile, its next-generation Dexcom G7 CGM has already launched in a number of countries overseas. The wearable device — which features a 60% size reduction from G6 — still awaits FDA clearance.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 25,2022

Senseonics Holdings, Inc. Schedules Third Quarter 2022 Earnings Release and Conference Call

Senseonics Holdings, Inc. today announced that it plans to release its third quarter 2022 financial results after market close on Tuesday, November 8, 2022. Management will hold a conference call to review the Company’s third quarter 2022 performance starting at 4:30 p.m. (Eastern Time) on the same day.

CONFERENCES

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 27,2022

Dexcom Reports Third Quarter 2022 Financial Results

DexCom today reported its financial results as of and for the quarter ended September 30, 2022. In the third quarter of 2022, worldwide revenue grew 18% to $769.6 million, up from $650.2 million in the third quarter of 2021. Volume growth in conjunction with strong new customer additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases.

#cgm

View Analyst & Ambassador Comments
Go to original news
Oct 28,2022

Abbott FreeStyle Libre named ‘best medical technology’ in last 50 years by Galien Foundation

Abbott announced today that the Galien Foundation picked its FreeStyle Libre continuous glucose monitor (CGM) for a major award. The foundation named FreeStyle Libre as the best “Best Medical Technology” of the last 50 years. Other medtech receiving the designation included Edwards Lifesciences’ Sapien 3 Ultra TAVR and Roche’s Cobas HPV test.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 04,2019

WaveForm Technologies and A. Menarini Diagnostics S.r.l. Enter Commercial Agreement for International Distribution of CGM Solutions

WaveForm Technologies Inc. a wholly owned subsidiary of WaveForm Diabetes (formerly AgaMatrix Holdings, LLC) and developer of novel products for continuous glucose monitoring, and A. Menarini Diagnostics S.r.l., a leading diagnostics company, today announced a partnership to commercialize the WaveForm Technologies Continuous Glucose Monitor (CGM). The innovative WaveForm CGM was specifically chosen to integrate within A. Menarini Diagnostics’ connected diabetes care platform. According to the agreement, A. Menarini Diagnostics will perform sales, marketing, training, and customer support for the WaveForm CGM in a long term partnership in territories throughout EMEA and LATAM.

COLLABORATION PARTNERSHIP

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 05,2019

WaveForm Technologies Inc Awarded CE Mark Approval for Their CGM System

WaveForm Technologies Inc. a wholly owned subsidiary of AgaMatrix Holdings, LLC and developer of novel continuous glucose monitoring products, today announced it has received CE Mark approval for its Cascade Continuous Glucose Monitoring (CGM) system. Commercialization of the product for the European market is anticipated to begin in select countries.

REGULATORY CE MARK

#cgm

#mobile app

View Analyst & Ambassador Comments
Go to original news
Mar 08,2018

WaveForm Technologies Receives Favorable Decision on Critical Glucose Monitoring Patents

WaveForm Technologies Inc. a developer of novel products for continuous glucose monitoring and a wholly owned subsidiary of WaveForm Diabetes (formerly AgaMatrix Holdings, LLC), announced that the Patent Trial and Appeal Board (PTAB) has ruled two early patents held by WaveForm are not invalid, based on challenges brought by Dexcom, Inc. (NASDAQ: DXCM). WaveForm and AgaMatrix believe that these recent legal victories support the value of its intellectual property and confirm the merits of its Oregon patent suit against Dexcom.

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 27,2022

Welldoc Presents Data Indicating Continuous Glucose Monitoring (CGM) Combined with a Digital Health Solution Leads to Significant Improvements in Glycemic Outcomes

Welldoc®, a digital health leader revolutionizing chronic care, today announced the presentation of data at the 15th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), evaluating how the combination of real-time CGM (Dexcom G6) with a digital health solution (BlueStar platform) impacts glucose control for individuals with Type 2 diabetes not treated with insulin. Data show that the largest improvements took place in the intermediate users’ cohort, which had a TIR increase of 32% and a GMI improvement of 1.4. TIR improvements as low as 5% have been demonstrated to be clinically significant, therefore these data strongly support the hypothesis that combining rtCGM with a digital health solution can lead to enhanced glucose control and improved patient outcomes.

CLINICAL STUDY

#mobile app

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

One Drop Study Signals Significant Growing Interest in Continuous Glucose Monitors (CGMs) Among People with Type 2 Diabetes

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented new research at the 82nd Scientific Sessions of the American Diabetes Association on attitudes and adoption of continuous glucose monitors (CGM) among people with type 2 diabetes (T2D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 14,2019

Senseonics Announces Partnership with Geo-Med to Provide Veterans Access to Eversense CGM

Senseonics Holdings today has announced that it has partnered with Geo-Med, LLC, a verified Service-Disabled Veteran-Owned Small Business (SDVOSB) to provide access to Eversense CGM to more than 9 million covered veterans and U.S. government personnel.

COLLABORATION COLLABORATION

#product & service

#cgm

View Analyst & Ambassador Comments
Go to original news
Subscribe to CGM